Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Leptomeningeal Disease
Interventions: DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Capecitabine
Sponsor: University of Alabama at Birmingham
Collaborators: Translational Breast Cancer Research Consortium|Johns Hopkins University|Seagen Inc.|University of Michigan|Georgetown University|University of California, San Francisco|University of Chicago|Indiana University|University of Washington|University of Texas